Literature DB >> 18177596

Psoriatic arthritis: current topics.

David McCarey1, Iain B McInnes.   

Abstract

Psoriatic arthritis is a common inflammatory arthropathy that occurs in approximately 25% of psoriasis patients. Due to significant advances in therapeutics--mainly the advent of biologic therapy--the disease has been subject to intense investigation recently. This review summarizes recent investigations of disease pathogenesis and clinical treatment. Clinical responses to tumor necrosis factor-blocking agents appear robust and superior to traditional disease-modifying drug responses, whereas other interventions, such as costimulation blockade, require more investigation. The pathogenesis of the disease appears related to T helper 17-polarized immune responses that target skin, joints, and the enthesial compartment. Finally, new insights into the disorder's genetic antecedents are emerging as more cohorts of patients undergo advanced genetic screening methods.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18177596     DOI: 10.1007/s11926-007-0072-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  47 in total

1.  Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

Authors:  D D Gladman; P J Mease; M A Cifaldi; R J Perdok; E Sasso; J Medich
Journal:  Ann Rheum Dis       Date:  2006-10-17       Impact factor: 19.103

Review 2.  Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis.

Authors:  Mike J Peters; Irene E van der Horst-Bruinsma; Ben A Dijkmans; Michael T Nurmohamed
Journal:  Semin Arthritis Rheum       Date:  2004-12       Impact factor: 5.532

3.  Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

Authors:  D D Gladman; V T Farewell; K Wong; J Husted
Journal:  Arthritis Rheum       Date:  1998-06

4.  Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.

Authors:  John Rømer; Erik Hasselager; Peder Lisby Nørby; Torben Steiniche; Jes Thorn Clausen; Knud Kragballe
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

5.  The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains.

Authors:  Simon Hör; Heide Pirzer; Laure Dumoutier; Finn Bauer; Sabine Wittmann; Heinrich Sticht; Jean-Christophe Renauld; René de Waal Malefyt; Helmut Fickenscher
Journal:  J Biol Chem       Date:  2004-06-03       Impact factor: 5.157

6.  Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.

Authors:  D van der Heijde; A Kavanaugh; D D Gladman; C Antoni; G G Krueger; C Guzzo; B Zhou; L T Dooley; K de Vlam; P Geusens; C Birbara; D Halter; A Beutler
Journal:  Arthritis Rheum       Date:  2007-08

7.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06

8.  HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis.

Authors:  Pauline Y P C Ho; Anne Barton; Jane Worthington; Wendy Thomson; Alan J Silman; Ian N Bruce
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

9.  VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.

Authors:  Christopher Butt; Sooyeol Lim; Celia Greenwood; Proton Rahman
Journal:  BMC Musculoskelet Disord       Date:  2007-01-04       Impact factor: 2.362

10.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.

Authors:  Jason R Chan; Wendy Blumenschein; Erin Murphy; Caroline Diveu; Maria Wiekowski; Susan Abbondanzo; Linda Lucian; Richard Geissler; Scott Brodie; Alexa B Kimball; Daniel M Gorman; Kathleen Smith; Rene de Waal Malefyt; Robert A Kastelein; Terrill K McClanahan; Edward P Bowman
Journal:  J Exp Med       Date:  2006-10-30       Impact factor: 14.307

View more
  2 in total

1.  Update on the treatment of peripheral arthritis in psoriatic arthritis.

Authors:  Enrique R Soriano; Javier Rosa
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 2.  Treatment recommendations for psoriatic arthritis.

Authors:  C T Ritchlin; A Kavanaugh; D D Gladman; P J Mease; P Helliwell; W-H Boehncke; K de Vlam; D Fiorentino; O Fitzgerald; A B Gottlieb; N J McHugh; P Nash; A A Qureshi; E R Soriano; W J Taylor
Journal:  Ann Rheum Dis       Date:  2008-10-24       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.